New York, December 28, 2023 – Microbot Medical Inc. (Nasdaq: MBOT) has completed its GLP pivotal pre-clinical study for the LIBERTY® Endovascular Robotic Surgical System. The study, adhering to FDA guidelines and using a porcine model, successfully met all its objectives, including conducting 96 robotic navigations by three interventional radiologists. This involved evaluating target vessels and surrounding tissues with the LIBERTY system controlling various intravascular catheterization devices.
Microbot shares rose 60% Thursday to $2.12, representing a 60% increase from its closing price on the previous day.
Juan Diaz Cartelle, Chief Medical Officer said, “I am very pleased with the positive outcomes of the histopathology report and the completion of the GLP study. This gives us confidence to move forward to the next stage of human clinical studies.”
Harel Gadot, CEO added, “Today’s announcement marks another important milestone for the Company, as we continue our transition from R&D and pre-clinical phase into the clinical, regulatory and pre-commercial phase. We expect to submit our IDE application to the FDA soon and commence our pivotal human clinical trial, completing our transition to a clinically stage company.”
MBOT is featured in the PRISM Emerging MedDevices Index
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is a pre-clinical medical device company that specializes in transformational micro-robotic technologies, with the goals of improving clinical outcomes for patients and increasing accessibility through the natural and artificial lumens within the human body.
The LIBERTY® Endovascular Robotic Surgical System aims to improve the way surgical robotics are being used in endovascular procedures today, by eliminating the need for large, cumbersome, and expensive capital equipment. The Company believes the LIBERTY® Endovascular Robotic Surgical System’s remote operation has the potential to be the first system to democratize endovascular interventional procedures.
.@MicrobotMedical is Set to Progress its Liberty Robotic System into Pivotal Clinical Trial; Shares soar 60%https://t.co/0mrb41lkeG $MBOT #Robotics #clinicalstudy #StocksInNews #prismmarketview #prismmediawire
— PrismMarketView (@PrismMarketView) December 28, 2023
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
PRISM MarketView does not provide investment advice.
Media Contact
Company Name: Prism MarketView
Email: info@prismmarketview.com
Phone: 646-863-6341
Country: United States
Website: https://prismmarketview.com
Social Media:
